<DOC>
	<DOCNO>NCT02375880</DOCNO>
	<brief_summary>DKN-01 humanize monoclonal antibody ( Mab ) neutralize activity Dkk-1 develop anti-neoplastic agent . This study design evaluate safety , tolerability , pharmacokinetics , anti-tumor activity DKN-01 combination gemcitabine cisplatin patient carcinoma primary intra- exta-hepatic biliary system gallbladder .</brief_summary>
	<brief_title>Study DKN-01 Gemcitabine/Cisplatin Patients With Carcinoma Primary Intra- Extra-Hepatic Biliary System Gallbladder</brief_title>
	<detailed_description>In Part A , escalate dos DKN-01 administer different cohort patient evaluate safety dose limit toxicity ( DLTs ) establish maximum tolerated dose DKN-01 administer combination gemcitabine cisplatin . Part B expansion cohort patient treat MTD DKN-01 ( high dose test MTD define ) characterize safety , tolerability , pharmacokinetics efficacy within define patient population .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Patient carcinoma primary intra extrahepatic biliary system gall bladder . 2 . Patient must sufficient tumor tissue available submission . 3 . For patient receive prior cryotherapy , radiofrequency ablation , radioembolization , ethanol injection , transarterial chemoembolization ( TACE ) photodynamic therapy , least 28 day must elapse since therapy , lesion treat local therapy must present measurable . 4 . Patients may receive prior adjuvant chemotherapy gemcitabine without cisplatin , long 6 month elapse since last treatment . 5 . Patients must one tumor measurable radiographic imaging define RECIST . 6 . ECOG PS 0 1 . Patients ECOG PS 2 may enter upon review approval medical monitor . 7 . Estimated life expectancy least 3 month . 8 . Diseasefree active second/secondary prior malignancy â‰¥ 2 year exception currently treat basal cell squamous cell carcinoma skin , carcinoma insitu cervix breast . 9 . Adequate hematological , renal , hepatic coagulation laboratory test result . 10 . Women child bear potential men must agree use adequate contraception study 6 month last dose study drug . 11 . Available duration study willing follow studyspecific procedure . 12 . Provide write informed consent 1 . New York Heart Association Class III IV cardiac disease , myocardial infarction within past 6 month , unstable arrhythmia . 2 . Have Fridericiacorrected QT interval ( QTcF ) &gt; 470 msec ( female ) &gt; 450 ( male ) , history congenital long QT syndrome . 3 . Active , uncontrolled bacterial , viral , fungal infection . 4 . Known human immunodeficiency virus ( HIV ) positive untreated , active hepatitis B . 5 . History major organ transplant . 6 . History autologous/allogenic bone marrow transplant . 7 . Serious nonmalignant disease . 8 . Pregnant nursing . 9 . History osteonecrosis hip evidence structural bone abnormality proximal femur MRI scan symptomatic clinically significant . 10 . Symptomatic central nervous system ( CNS ) malignancy metastasis . 11 . Clinically significant peripheral neuropathy 12 . Known osteoblastic bony metastasis . 13 . Treatment surgery chemotherapy within 21 day prior study entry radiation within 14 day study entry . 14 . Previously treat antiDkk1 therapy . 15 . Other exclusion apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>